Sentence examples for mouse tumour section from inspiring English sources

Mouse tumour section was imaged by 80 FPA tiles (X = 16 and Y = 5).

Images from the mouse tumour section served as a model for testing pixel binning to assess spectral quality versus good spatial resolution.

For revealing blood vessel location in parallel tissue sections and defining the regions of interest, IHC using CD31 antibody (for mouse tumour section) or CD34 antibody (for human tumour section) was performed (as previously described in [ 13] and [ 14]).

Figure  1 shows the mouse tumour section imaged in different binning modes, the effective pixel size increases, but the number of spectra and the acquisition time reduce when higher binning is performed.

Immunostaining of frozen mouse tumour sections to quantify blood vessel density was done using anti-PECAM antibody (BD Biosciences, San Jose, CA, USA) as described previously (Reynolds et al, 2002).

To detect RRM2, CD31 and phospho-ERK1/2 within Human cervical cancer tissue sections or mouse tumour sections, the primary antibody was incubated at 4 °C overnight, and horseradish peroxidase-conjugated secondary antibody was then added.

Immunostaining of frozen mouse tumour sections to detect blood vessels with CD31 antibody was performed as described (Reynolds et al., 2002) and the samples mounted with ProLong Gold anti-fade reagent with DAPI (Invitrogen).

First, we assessed the FPA performances using different binning modes by quickly screening mouse tumour tissue sections as a test to determine which binning option is the best.

To stain blood vessels, human GBM tissue slides were incubated with Ulex europaeus I agglutinin (ULEX) (1 : 20; Vector Laboratories, Burlington, ON, Canada) for 3 min at RT, whereas mouse GBM tumour sections were incubated with rat anti-mouse CD31 primary antibody for 1 h at RT followed by goat anti-rat alexa 568 secondary antibody (1 : 300) for 1 h at RT.

Furthermore, these antibodies are able to strongly stain frozen sections of an SCC-like mouse tumour based on the A431 epidermoid carcinoma cells, xenografted subcutaneously in nude mice (Supplementary Figure S2).

In order to validate that ZOL induces changes in follistatin and pSmad2L in ER-ve tumours in vivo, ER-ve MDA-MB-436 sub-cutaneous tumour sections from mice treated with or without ZOL (100 μg/kg, weekly for 6 weeks, equivalent to the 4 mg clinical dose) were evaluated.